NCT06974110 2026-04-15
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
MOMA Therapeutics
Astellas Pharma Inc
National Cancer Institute (NCI)
Eli Lilly and Company
Actuate Therapeutics Inc.
Novartis